Glaukos announces licensing deal with Attillaps for pharmaceutical compounds

Glaukos (NYSE:GKOS) announced today that it entered into a licensing agreement with Attillaps for its library of pharmaceutical compounds.

San Clemente, California-based Glaukos was granted a global exclusive license to research, develop, manufacture and commercialize Attillaps’ proprietary library of investigational pharmaceutical compounds that target the eradication of Demodex mites — the root cause of Demodex blepharitis often associated with meibomian gland dysfunction and related ophthalmic diseases.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0